WO2001073131A1 - High specificity marker detection - Google Patents
High specificity marker detection Download PDFInfo
- Publication number
- WO2001073131A1 WO2001073131A1 PCT/US2001/009789 US0109789W WO0173131A1 WO 2001073131 A1 WO2001073131 A1 WO 2001073131A1 US 0109789 W US0109789 W US 0109789W WO 0173131 A1 WO0173131 A1 WO 0173131A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- marker
- mrna
- sample
- cell
- Prior art date
Links
- 239000003550 marker Substances 0.000 title claims abstract description 48
- 238000001514 detection method Methods 0.000 title description 28
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 101
- 238000000034 method Methods 0.000 claims abstract description 90
- 239000002771 cell marker Substances 0.000 claims abstract description 58
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 50
- 201000011510 cancer Diseases 0.000 claims abstract description 46
- 238000013518 transcription Methods 0.000 claims abstract description 43
- 230000035897 transcription Effects 0.000 claims abstract description 43
- 210000004027 cell Anatomy 0.000 claims description 192
- 108010001687 Enterotoxin Receptors Proteins 0.000 claims description 97
- 102000000820 Enterotoxin Receptors Human genes 0.000 claims description 97
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 77
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 77
- 238000003757 reverse transcription PCR Methods 0.000 claims description 60
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 52
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 52
- 210000004369 blood Anatomy 0.000 claims description 47
- 239000008280 blood Substances 0.000 claims description 47
- 210000001519 tissue Anatomy 0.000 claims description 44
- 238000003752 polymerase chain reaction Methods 0.000 claims description 39
- 210000002919 epithelial cell Anatomy 0.000 claims description 22
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 19
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 19
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 17
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 17
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 claims description 16
- 108010066370 Keratin-20 Proteins 0.000 claims description 16
- 108010008707 Mucin-1 Proteins 0.000 claims description 16
- 102000007298 Mucin-1 Human genes 0.000 claims description 16
- 210000004072 lung Anatomy 0.000 claims description 15
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 14
- 108010066302 Keratin-19 Proteins 0.000 claims description 14
- 210000001072 colon Anatomy 0.000 claims description 14
- 239000013641 positive control Substances 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 210000001124 body fluid Anatomy 0.000 claims description 12
- 210000001185 bone marrow Anatomy 0.000 claims description 11
- 239000013642 negative control Substances 0.000 claims description 11
- 102000018329 Keratin-18 Human genes 0.000 claims description 7
- 108010066327 Keratin-18 Proteins 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 7
- 208000037819 metastatic cancer Diseases 0.000 claims description 7
- 102100034343 Integrase Human genes 0.000 claims description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 6
- 108060008724 Tyrosinase Proteins 0.000 claims description 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 6
- 102000006277 CDX2 Transcription Factor Human genes 0.000 claims description 5
- 108010083123 CDX2 Transcription Factor Proteins 0.000 claims description 5
- 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 claims description 5
- 102100027918 Sucrase-isomaltase, intestinal Human genes 0.000 claims description 5
- 108010034949 Thyroglobulin Proteins 0.000 claims description 5
- 102000009843 Thyroglobulin Human genes 0.000 claims description 5
- 102000003425 Tyrosinase Human genes 0.000 claims description 5
- 229960002175 thyroglobulin Drugs 0.000 claims description 5
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 3
- 102000003846 Carbonic anhydrases Human genes 0.000 claims description 3
- 108090000209 Carbonic anhydrases Proteins 0.000 claims description 3
- 101150096994 Cdx1 gene Proteins 0.000 claims description 3
- 102000029792 Desmoplakin Human genes 0.000 claims description 3
- 108091000074 Desmoplakin Proteins 0.000 claims description 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 3
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 3
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 3
- 108010059881 Lactase Proteins 0.000 claims description 3
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims description 3
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 229940116108 lactase Drugs 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 239000000523 sample Substances 0.000 description 68
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 64
- 239000013615 primer Substances 0.000 description 57
- 210000005087 mononuclear cell Anatomy 0.000 description 46
- 239000000047 product Substances 0.000 description 33
- 210000000130 stem cell Anatomy 0.000 description 32
- 206010009944 Colon cancer Diseases 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 28
- 238000005516 engineering process Methods 0.000 description 27
- 239000000499 gel Substances 0.000 description 24
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 19
- 101150073133 Cpt1a gene Proteins 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 16
- 206010006187 Breast cancer Diseases 0.000 description 14
- 208000026310 Breast neoplasm Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 11
- 229960005542 ethidium bromide Drugs 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 239000010839 body fluid Substances 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 9
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 8
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 108091093088 Amplicon Proteins 0.000 description 7
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 7
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000002980 postoperative effect Effects 0.000 description 6
- 210000000664 rectum Anatomy 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010061819 Disease recurrence Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000005382 thermal cycling Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000011072 cell harvest Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 238000010324 immunological assay Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 1
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000037323 Rare tumor Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001825 field-flow fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000005339 levitation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001249503A AU2001249503A1 (en) | 2000-03-27 | 2001-03-27 | High specificity marker detection |
JP2001570844A JP2003535580A (en) | 2000-03-27 | 2001-03-27 | High specificity marker detection |
EP01922738A EP1268854A4 (en) | 2000-03-27 | 2001-03-27 | High specificity marker detection |
CA002404428A CA2404428A1 (en) | 2000-03-27 | 2001-03-27 | High specificity marker detection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19222900P | 2000-03-27 | 2000-03-27 | |
US60/192,229 | 2000-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001073131A1 true WO2001073131A1 (en) | 2001-10-04 |
Family
ID=22708782
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/009789 WO2001073131A1 (en) | 2000-03-27 | 2001-03-27 | High specificity marker detection |
PCT/US2001/009790 WO2001073132A1 (en) | 2000-03-27 | 2001-03-27 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
PCT/US2001/009918 WO2001073133A1 (en) | 2000-03-27 | 2001-03-27 | Compositions and methods for identifying and targeting cancer cells |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/009790 WO2001073132A1 (en) | 2000-03-27 | 2001-03-27 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
PCT/US2001/009918 WO2001073133A1 (en) | 2000-03-27 | 2001-03-27 | Compositions and methods for identifying and targeting cancer cells |
Country Status (10)
Country | Link |
---|---|
US (20) | US20010036635A1 (en) |
EP (6) | EP3388534A1 (en) |
JP (3) | JP5122713B2 (en) |
AT (2) | ATE452989T1 (en) |
AU (3) | AU2001249503A1 (en) |
CA (3) | CA2404428A1 (en) |
DE (2) | DE60140865D1 (en) |
ES (2) | ES2346637T3 (en) |
PT (1) | PT1272665E (en) |
WO (3) | WO2001073131A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8535914B2 (en) * | 2005-01-21 | 2013-09-17 | Canon Kabushiki Kaisha | Probe, probe set and information acquisition method using the same |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097839B1 (en) * | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5879656A (en) * | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
US6692952B1 (en) * | 1999-11-10 | 2004-02-17 | Massachusetts Institute Of Technology | Cell analysis and sorting apparatus for manipulation of cells |
DE60140865D1 (en) * | 2000-03-27 | 2010-02-04 | Univ Jefferson | COMPOSITIONS AND METHODS OF IDENTIFYING CANCER CELLS |
WO2002022885A1 (en) * | 2000-09-18 | 2002-03-21 | Thomas Jefferson University | Compositions and methods for identifying and targeting stomach and esophageal cancer cells |
WO2002074979A2 (en) * | 2001-03-20 | 2002-09-26 | Ortho-Clinical Diagnostics, Inc. | Expression profiles and methods of use |
ES2375724T3 (en) * | 2002-09-27 | 2012-03-05 | The General Hospital Corporation | MICROFLUDE DEVICE FOR SEPERATION OF CELLS AND ITS USES. |
WO2004044178A2 (en) * | 2002-11-13 | 2004-05-27 | Genentech, Inc. | Methods and compositions for diagnosing dysplasia |
DE10259703A1 (en) * | 2002-12-19 | 2004-07-08 | Ivonex Gmbh | separation process |
US7422865B2 (en) * | 2003-01-13 | 2008-09-09 | Agilent Technologies, Inc. | Method of identifying peptides in a proteomic sample |
US8206704B2 (en) | 2003-02-10 | 2012-06-26 | Thomas Jefferson University | Use of GCC ligands |
WO2004077021A2 (en) * | 2003-02-27 | 2004-09-10 | Lesko Stephen A | Standardized evaluation of therapeutic efficacy based on cellular biomarkers |
US10533998B2 (en) | 2008-07-18 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
US20070160503A1 (en) * | 2003-06-13 | 2007-07-12 | Palaniappan Sethu | Microfluidic systems for size based removal of red blood cells and platelets from blood |
CA2526284C (en) | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
DE602004024539D1 (en) * | 2003-07-03 | 2010-01-21 | Gentron Llc | METHOD AND SYSTEMS FOR DIAGNOSIS OF NON-DISTRACTIVE CNS DISEASES IN CNS SAMPLES |
EP1670511B1 (en) * | 2003-09-15 | 2009-07-29 | Research Development Foundation | Cripto antagonism of activin and tgf-b signaling |
WO2005040163A1 (en) * | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
AU2004289539C1 (en) | 2003-11-14 | 2012-06-07 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
AU2005218622A1 (en) * | 2004-03-03 | 2005-09-15 | Living Microsystems | Magnetic device for isolation of cells and biomolecules in a microfluidic environment |
US20050221339A1 (en) * | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
EP1781339B1 (en) | 2004-06-25 | 2013-12-25 | Thomas Jefferson University | Guanylyl cyclase C ligands |
EP2272987A3 (en) * | 2004-07-09 | 2012-04-11 | University of Pittsburgh of the Commonwealth System of Higher Education | Identification of markers in esophageal cancer, colon cancer, head and neck cancer and melanoma |
US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
US20070026415A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026417A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026414A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070196820A1 (en) * | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
US20070026413A1 (en) * | 2005-07-29 | 2007-02-01 | Mehmet Toner | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US8921102B2 (en) * | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070059680A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for cell enrichment |
US20070026416A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20090181421A1 (en) * | 2005-07-29 | 2009-07-16 | Ravi Kapur | Diagnosis of fetal abnormalities using nucleated red blood cells |
US7939649B2 (en) * | 2005-09-06 | 2011-05-10 | Stanford University | Polynucleotide encoding luciferase |
US20070059781A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for size based separation and analysis |
US20070059774A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Kits for Prenatal Testing |
US20070059683A1 (en) * | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
AU2006330947B2 (en) | 2005-12-22 | 2012-04-12 | Pacific Biosciences Of California, Inc. | Polymerases for nucleotide analogue incorporation |
AU2006331677A1 (en) * | 2005-12-22 | 2007-07-05 | Pacific Biosciences Of California, Inc. | Protein engineering strategies to optimize activity of surface attached proteins |
CA2633476C (en) * | 2005-12-22 | 2015-04-21 | Pacific Biosciences Of California, Inc. | Active surface coupled polymerases |
WO2007081386A2 (en) | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Microfluidic devices and methods of use |
JP2007215412A (en) * | 2006-02-14 | 2007-08-30 | Shizuoka Prefecture | Method for judging malignant metastatic stomach cancer |
US20070207467A1 (en) * | 2006-03-01 | 2007-09-06 | Ming Xu | Detection of lymph node metastasis from gastric carcinoma |
US20080014589A1 (en) | 2006-05-11 | 2008-01-17 | Link Darren R | Microfluidic devices and methods of use thereof |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
BRPI0713098A2 (en) * | 2006-05-22 | 2012-10-16 | Clinical Genomics Pty Ltd | method for determining the anatomical origin of an individual's large intestine-derived cell or cell population, detection method for determining the anatomical origin of an individual's large intestine-derived cell or cell population, detection system, legible storage medium by computer, nucleic acid arrangement, use of an arrangement, method for determining the onset or predisposition for the onset of a cellular abnormality or a condition distinguished by a cellular abnormality in the large intestine, diagnostic kit for assaying biological samples |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080070792A1 (en) | 2006-06-14 | 2008-03-20 | Roland Stoughton | Use of highly parallel snp genotyping for fetal diagnosis |
US20080050739A1 (en) * | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
EP2589668A1 (en) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Rare cell analysis using sample splitting and DNA tags |
EP2077912B1 (en) | 2006-08-07 | 2019-03-27 | The President and Fellows of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
ATE522813T1 (en) * | 2006-09-07 | 2011-09-15 | Universitaetsklinikum Hamburg | METHOD FOR DETECTING CARCINOMATOUS EPITHELIAL CELLS USING RELEASED CYTOKERATINS AS A MARKER FOR THESE CELLS |
WO2008051530A2 (en) * | 2006-10-23 | 2008-05-02 | Pacific Biosciences Of California, Inc. | Polymerase enzymes and reagents for enhanced nucleic acid sequencing |
US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US8679759B2 (en) * | 2007-08-01 | 2014-03-25 | The Johns Hopkins University | Esophageal cancer markers |
CA2706442C (en) * | 2007-11-27 | 2017-07-11 | Veridex, Llc | Automated enumeration and characterization of circulating melanoma cells in blood |
US20110195415A1 (en) * | 2008-05-13 | 2011-08-11 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
WO2010009365A1 (en) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Droplet libraries |
SI2334812T1 (en) | 2008-09-20 | 2017-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Building 170 | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
WO2010096929A1 (en) | 2009-02-25 | 2010-09-02 | Diagnocure Inc. | Method for detecting metastasis of gi cancer |
US8528589B2 (en) | 2009-03-23 | 2013-09-10 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
EP2486409A1 (en) | 2009-10-09 | 2012-08-15 | Universite De Strasbourg | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
EP2491116A4 (en) | 2009-10-22 | 2013-12-11 | Univ Jefferson | Cell-based anti-cancer compositions and methods of making and using the same |
IN2012DN02604A (en) * | 2009-10-23 | 2015-09-04 | Millennium Pharm Inc | |
CA2778639A1 (en) * | 2009-11-05 | 2011-05-12 | Sequent Medical Inc. | Multiple layer filamentary devices or treatment of vascular defects |
GB0920014D0 (en) * | 2009-11-13 | 2009-12-30 | Medical Res Council | Cell sampling device |
US8187979B2 (en) * | 2009-12-23 | 2012-05-29 | Varian Semiconductor Equipment Associates, Inc. | Workpiece patterning with plasma sheath modulation |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US9217032B2 (en) * | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
WO2011100604A2 (en) | 2010-02-12 | 2011-08-18 | Raindance Technologies, Inc. | Digital analyte analysis |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
PL2550294T3 (en) | 2010-03-24 | 2020-03-31 | Progastrine Et Cancers S.À R.L. | Prophylaxis of colorectal and gastrointestinal cancer |
US8932866B2 (en) | 2010-04-06 | 2015-01-13 | Kagoshima University | Method for inspecting gastroenterological cancer by utilizing N-linked sugar chain |
EP3447155A1 (en) | 2010-09-30 | 2019-02-27 | Raindance Technologies, Inc. | Sandwich assays in droplets |
WO2012109600A2 (en) | 2011-02-11 | 2012-08-16 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
WO2012112804A1 (en) | 2011-02-18 | 2012-08-23 | Raindance Technoligies, Inc. | Compositions and methods for molecular labeling |
EP2686688B1 (en) | 2011-03-17 | 2019-05-08 | Cernostics, Inc. | Systems and compositions for diagnosing barrett's esophagus and methods of using the same |
CN102311458A (en) * | 2011-05-31 | 2012-01-11 | 江苏省原子医学研究所 | <99m>TcO-nucleus-labeled chlorambucil complex as well as preparing and separating and purifying methods and application thereof |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
US20140363825A1 (en) * | 2011-08-29 | 2014-12-11 | Kyoto University | Marker for detecting colorectal cancer or esophageal cancer and method for examining such cancer |
JP2013083490A (en) | 2011-10-06 | 2013-05-09 | Kagoshima Univ | Marker for diagnosing gastrointestinal cancer, and method for inspecting gastrointestinal cancer |
WO2013120089A1 (en) | 2012-02-10 | 2013-08-15 | Raindance Technologies, Inc. | Molecular diagnostic screening assay |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
PE20142322A1 (en) | 2012-04-27 | 2015-01-25 | Millennium Pharm Inc | ANTI-GCC ANTIBODY MOLECULES AND USE OF THEM TO TEST SUSCEPTIBILITY TO GCC TARGETED THERAPY |
WO2013165748A1 (en) | 2012-04-30 | 2013-11-07 | Raindance Technologies, Inc | Digital analyte analysis |
JP6352909B2 (en) | 2012-06-27 | 2018-07-04 | バーグ エルエルシー | Use of markers in the diagnosis and treatment of prostate cancer |
US9396532B2 (en) * | 2012-11-15 | 2016-07-19 | Siemens Healthcare Diagnostics, Inc. | Cell feature-based automatic circulating tumor cell detection |
CN105142664A (en) * | 2013-02-28 | 2015-12-09 | 米伦纽姆医药公司 | Administration of an anti-GCC antibody-drug conjugate and a DNA damaging agent in the treatment of cancer |
EP2986762B1 (en) | 2013-04-19 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
DK3052102T3 (en) | 2013-10-04 | 2020-03-09 | Aptose Biosciences Inc | CANCER TREATMENT COMPOSITIONS |
US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
EP3090063B1 (en) | 2013-12-31 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Method for detection of latent retrovirus |
US20170067912A1 (en) * | 2014-03-13 | 2017-03-09 | The Penn State Research Foundation | Compositions and methods for diagnosing barrett's esophagus stages |
CA2970143A1 (en) | 2014-12-08 | 2016-06-16 | Berg Llc | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
KR20180026659A (en) | 2015-03-18 | 2018-03-13 | 더 존스 홉킨스 유니버시티 | A novel monoclonal antibody inhibitor targeting the potassium channel KCNK9 |
CN108135875B (en) | 2015-07-31 | 2021-12-31 | 约翰霍普金斯大学 | Methods and compositions for treating metabolic reprogramming disorders |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
EP3786640B1 (en) | 2015-11-25 | 2022-08-24 | Cernostics, Inc. | Methods of detecting malignant transformation of barrett's esophagus |
GB201604806D0 (en) * | 2016-03-22 | 2016-05-04 | Singapore Volition Pte Ltd | Method of identifying a cancer of unknown origin |
CN106124764B (en) * | 2016-08-12 | 2018-03-09 | 上海市嘉定区中心医院 | Stomach cancer detection kit and application using HOXB9 and PBX1 as biomarker |
KR101966642B1 (en) | 2017-03-14 | 2019-04-09 | (주) 노보믹스 | System for predicting prognosis and benefit from adjuvant chemotherapy for patients with stage II and III gastric cancer |
KR20200108409A (en) * | 2017-08-18 | 2020-09-18 | 토마스 제퍼슨 유니버시티 | Protection of normal tissues in cancer treatment |
US10998178B2 (en) | 2017-08-28 | 2021-05-04 | Purdue Research Foundation | Systems and methods for sample analysis using swabs |
US11773449B2 (en) | 2017-09-01 | 2023-10-03 | The Hospital For Sick Children | Profiling and treatment of hypermutant cancer |
KR20200096914A (en) | 2017-10-30 | 2020-08-14 | 압토스 바이오사이언시스 인코포레이티드 | Aryl imidazole for cancer treatment |
FI128634B (en) * | 2019-06-07 | 2020-09-15 | Nokia Solutions & Networks Oy | Providing information |
TW202237639A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
TW202237638A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6130043A (en) * | 1997-05-02 | 2000-10-10 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3130883A (en) * | 1962-03-01 | 1964-04-28 | Lewis J Mackool | Hatchet scabbard |
US4375414A (en) | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
US4022878A (en) | 1972-05-15 | 1977-05-10 | Biological Developments, Inc. | Methods and compounds for producing specific antibodies |
US4526716A (en) | 1981-11-20 | 1985-07-02 | The Ohio State University | Antigenic modification of polypeptides |
US4329281A (en) | 1978-06-05 | 1982-05-11 | Hoffmann-La Roche Inc. | Hapten compositions |
US4264024A (en) * | 1978-12-21 | 1981-04-28 | Harris Jr Ellsworth L | Smoking pipe sling |
US4341763A (en) | 1981-03-10 | 1982-07-27 | Smithkline-Rit | Methods of vaccinating humans against rotavirus infection |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4584268A (en) | 1981-10-13 | 1986-04-22 | Ceriani Roberto Luis | Method and compositions for carcinoma diagnosis |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
GB8328918D0 (en) | 1983-10-28 | 1983-11-30 | Unilever Plc | Alkaline phosphatase |
ZA839512B (en) | 1983-12-12 | 1984-08-29 | Scripps Clinic Res | Synthetic heat-stable enterotoxin polypeptide of escherichia coli and multimers thereof |
US4601896A (en) | 1984-03-21 | 1986-07-22 | Mark Nugent | Pharmaceutical capsule compositions and structures for gastric sensitive materials |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4729893A (en) | 1984-12-26 | 1988-03-08 | Robert L. Letcher | Enteric encapsulation of ancrod for oral administration |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US5160723A (en) | 1985-04-19 | 1992-11-03 | Sloan-Kettering Institute For Cancer Research | Method of imaging colorectal carcinoma lesion and composition for use therein |
GB8519457D0 (en) | 1985-08-02 | 1985-09-11 | Faulk Ward Page | Tumour imaging agents |
JPS62162963A (en) | 1986-01-10 | 1987-07-18 | Sadao Shiosaka | Specific antibody of low molecular material prepared by using metallic colloid particle as carrier and preparation thereof |
US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
IN165717B (en) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US5399347A (en) | 1987-06-24 | 1995-03-21 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
US5217869A (en) | 1987-10-13 | 1993-06-08 | Terrapin Technologies, Inc. | Method to produce immunodiagnostic reagents |
US4963263A (en) | 1988-03-24 | 1990-10-16 | Terrapin Technologies, Inc. | Method of identity analyte-binding peptides |
US5133866A (en) | 1988-03-24 | 1992-07-28 | Terrapin Technologies, Inc. | Method to identify analyte-bending ligands |
US5340474A (en) | 1988-03-24 | 1994-08-23 | Terrapin Technologies, Inc. | Panels of analyte-binding ligands |
US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
US4923949A (en) | 1988-08-03 | 1990-05-08 | Kanegafuchi Chemical Industry Co., Ltd. | Ethynylene-disilanylene copolymers and method of preparing same |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
US5049656A (en) | 1988-12-21 | 1991-09-17 | Board Of Regents Of The University Of Nebraska | Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques |
ES2200016T3 (en) | 1989-03-21 | 2004-03-01 | Vical Incorporated | EXPRESSION OF EXECUTIVE POLINUCLEOTIDIC SEQUENCES IN A VERTEBRATE. |
US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5443816A (en) | 1990-08-08 | 1995-08-22 | Rhomed Incorporated | Peptide-metal ion pharmaceutical preparation and method |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
US5366862A (en) | 1990-02-14 | 1994-11-22 | Receptor Laboratories, Inc. | Method for generating and screening useful peptides |
CA2039517C (en) * | 1990-04-03 | 2006-11-07 | David Segev | Dna probe signal amplification |
US5430138A (en) | 1990-07-27 | 1995-07-04 | Chiron Corporation | Hydroxyl-protecting groups attached to cytidine nucleotide compounds which are orthogonally removable |
US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
US5352775A (en) | 1991-01-16 | 1994-10-04 | The Johns Hopkins Univ. | APC gene and nucleic acid probes derived therefrom |
KR930702985A (en) | 1991-02-21 | 1993-11-29 | 스튜어트 알.슈터 | Treatment of Esophageal Cancer |
US5330892A (en) | 1991-03-13 | 1994-07-19 | The Johns Hopkins University | MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans |
AU662906B2 (en) | 1991-06-26 | 1995-09-21 | F. Hoffmann-La Roche Ag | Methods for detection of carcinoma metastases by nucleic acid amplification |
US5140102A (en) * | 1991-09-23 | 1992-08-18 | Monsanto Company | Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
US5395750A (en) | 1992-02-28 | 1995-03-07 | Hoffmann-La Roche Inc. | Methods for producing proteins which bind to predetermined antigens |
US5969097A (en) * | 1992-06-23 | 1999-10-19 | G. D. Searle & Co. | Human guanylin |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
US5420328A (en) | 1992-09-11 | 1995-05-30 | Affymax Technologies, N.V. | Methods for the synthesis of phosphonate esters |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5324483B1 (en) | 1992-10-08 | 1996-09-24 | Warner Lambert Co | Apparatus for multiple simultaneous synthesis |
US5397639A (en) | 1992-11-25 | 1995-03-14 | Tollini; Dennis R. | Securing tape |
US5595739A (en) | 1993-05-07 | 1997-01-21 | Abbott Laboratories | Hepatitis B virus mutants, reagents and methods for detection |
US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5601990A (en) * | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
CA2174928C (en) | 1993-10-26 | 2011-08-16 | Scott A. Waldman | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
US7097839B1 (en) * | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5962220A (en) | 1993-10-26 | 1999-10-05 | Thomas Jefferson University | Compositions that specifically bind to colorectal cells and methods of using the same |
US5489670A (en) * | 1993-10-29 | 1996-02-06 | G. D. Searle & Co. | Human uroguanylin |
US5885574A (en) * | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5597909A (en) * | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5858011A (en) | 1995-08-02 | 1999-01-12 | The Procter & Gamble Company | Disposable absorbent article having a resilient member |
EP0891550A1 (en) * | 1996-04-05 | 1999-01-20 | The Johns Hopkins University School Of Medicine | A method of enriching rare cells |
CA2224970C (en) * | 1996-04-16 | 2002-04-02 | Kishimoto, Tadamitsu | Method of detecting solid cancer cells and tissue atypia and method of testing tissues for use in bone marrow transplantation and peripheral blood stem cell transplantation |
WO1997042506A1 (en) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
DE69723580T2 (en) | 1996-05-03 | 2004-06-03 | Thomas Jefferson University | Vaccine against metastatic colorectal cancer. |
US5914238A (en) * | 1996-06-05 | 1999-06-22 | Matritech, Inc. | Materials and methods for detection of breast cancer |
AU4003597A (en) * | 1996-09-04 | 1998-03-26 | Howard Florey Institute Of Experimental Physiology And Medicine | Methods of diagnosing and treating cancer |
FI971124A0 (en) * | 1997-03-18 | 1997-03-18 | Locus Genex Oy | Method Foer diagnosis av magcancer |
US5874266A (en) * | 1997-03-27 | 1999-02-23 | Palsson; Bernhard O. | Targeted system for removing tumor cells from cell populations |
US6120995A (en) * | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
JP2002526760A (en) * | 1998-10-02 | 2002-08-20 | ダイアデクスアス・インコーポレーテッド | Novel method for diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer |
WO2000047998A1 (en) * | 1999-02-10 | 2000-08-17 | Cell Works Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
EP2325321A1 (en) * | 1999-05-28 | 2011-05-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
DE60140865D1 (en) * | 2000-03-27 | 2010-02-04 | Univ Jefferson | COMPOSITIONS AND METHODS OF IDENTIFYING CANCER CELLS |
WO2002022885A1 (en) * | 2000-09-18 | 2002-03-21 | Thomas Jefferson University | Compositions and methods for identifying and targeting stomach and esophageal cancer cells |
US6652378B2 (en) | 2001-06-01 | 2003-11-25 | Igt | Gaming machines and systems offering simultaneous play of multiple games and methods of gaming |
US20050257067A1 (en) * | 2002-08-30 | 2005-11-17 | Roberts David K | Fingerprint embedding |
US8206704B2 (en) * | 2003-02-10 | 2012-06-26 | Thomas Jefferson University | Use of GCC ligands |
EP1781339B1 (en) * | 2004-06-25 | 2013-12-25 | Thomas Jefferson University | Guanylyl cyclase C ligands |
DE102005041131B4 (en) | 2005-08-30 | 2008-01-31 | Phoenix Contact Gmbh & Co. Kg | exchangers |
US9001515B2 (en) | 2012-04-20 | 2015-04-07 | Cisco Technology, Inc. | Universal pull tab release for modules including fiber optic and cable accessibilities |
US9707467B2 (en) | 2013-10-18 | 2017-07-18 | Under Armour, Inc. | Athletic glove |
US9707565B2 (en) | 2014-04-09 | 2017-07-18 | II Lyman Burdette Lyne | Screen assembly for shredding machine |
-
2001
- 2001-03-27 DE DE60140865T patent/DE60140865D1/en not_active Expired - Lifetime
- 2001-03-27 DE DE60142228T patent/DE60142228D1/en not_active Expired - Lifetime
- 2001-03-27 EP EP18170703.5A patent/EP3388534A1/en not_active Withdrawn
- 2001-03-27 US US09/819,247 patent/US20010036635A1/en not_active Abandoned
- 2001-03-27 EP EP01922785A patent/EP1274861B1/en not_active Expired - Lifetime
- 2001-03-27 US US09/819,248 patent/US20010039016A1/en not_active Abandoned
- 2001-03-27 ES ES01922739T patent/ES2346637T3/en not_active Expired - Lifetime
- 2001-03-27 AT AT01922785T patent/ATE452989T1/en not_active IP Right Cessation
- 2001-03-27 EP EP01922738A patent/EP1268854A4/en not_active Withdrawn
- 2001-03-27 US US09/819,254 patent/US20010029020A1/en not_active Abandoned
- 2001-03-27 AU AU2001249503A patent/AU2001249503A1/en not_active Abandoned
- 2001-03-27 EP EP10163844.3A patent/EP2230320B1/en not_active Expired - Lifetime
- 2001-03-27 WO PCT/US2001/009789 patent/WO2001073131A1/en not_active Application Discontinuation
- 2001-03-27 EP EP01922739A patent/EP1272665B1/en not_active Expired - Lifetime
- 2001-03-27 JP JP2001570846A patent/JP5122713B2/en not_active Expired - Fee Related
- 2001-03-27 JP JP2001570844A patent/JP2003535580A/en active Pending
- 2001-03-27 AT AT01922739T patent/ATE469242T1/en not_active IP Right Cessation
- 2001-03-27 US US09/820,215 patent/US20020012931A1/en not_active Abandoned
- 2001-03-27 ES ES10163844.3T patent/ES2548381T3/en not_active Expired - Lifetime
- 2001-03-27 WO PCT/US2001/009790 patent/WO2001073132A1/en active Application Filing
- 2001-03-27 US US09/819,249 patent/US6767704B2/en not_active Expired - Lifetime
- 2001-03-27 AU AU2001249504A patent/AU2001249504A1/en not_active Abandoned
- 2001-03-27 JP JP2001570845A patent/JP2003528628A/en not_active Ceased
- 2001-03-27 PT PT01922739T patent/PT1272665E/en unknown
- 2001-03-27 US US09/819,252 patent/US6844153B2/en not_active Expired - Fee Related
- 2001-03-27 CA CA002404428A patent/CA2404428A1/en not_active Abandoned
- 2001-03-27 CA CA002404432A patent/CA2404432A1/en not_active Abandoned
- 2001-03-27 EP EP15174679.9A patent/EP2949762B1/en not_active Expired - Lifetime
- 2001-03-27 AU AU2001249548A patent/AU2001249548A1/en not_active Abandoned
- 2001-03-27 CA CA2404431A patent/CA2404431C/en not_active Expired - Lifetime
- 2001-03-27 WO PCT/US2001/009918 patent/WO2001073133A1/en active Application Filing
-
2003
- 2003-05-02 US US10/428,225 patent/US20040033520A1/en not_active Abandoned
- 2003-06-30 US US10/611,533 patent/US7745114B2/en not_active Expired - Fee Related
-
2004
- 2004-06-14 US US10/866,951 patent/US7854933B2/en not_active Expired - Lifetime
-
2005
- 2005-01-14 US US11/036,875 patent/US7479376B2/en not_active Expired - Fee Related
- 2005-02-16 US US11/058,778 patent/US7485422B2/en not_active Expired - Fee Related
-
2008
- 2008-02-25 US US12/036,875 patent/US20080241064A1/en not_active Abandoned
- 2008-11-17 US US12/272,593 patent/US7785817B2/en not_active Expired - Fee Related
-
2009
- 2009-09-04 US US12/554,572 patent/US20100015167A1/en not_active Abandoned
-
2010
- 2010-06-28 US US12/824,897 patent/US20110250228A1/en not_active Abandoned
- 2010-08-20 US US12/860,835 patent/US20110086064A1/en not_active Abandoned
- 2010-12-06 US US12/961,373 patent/US8067007B2/en not_active Expired - Fee Related
-
2011
- 2011-10-20 US US13/277,612 patent/US8946168B2/en not_active Expired - Fee Related
-
2014
- 2014-10-22 US US14/520,962 patent/US9429576B2/en not_active Expired - Fee Related
-
2016
- 2016-08-26 US US15/249,291 patent/US20170049869A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6130043A (en) * | 1997-05-02 | 2000-10-10 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
Non-Patent Citations (1)
Title |
---|
CAGIR B. ET AL.: "Guanylyl Cyclase C Messenger RNA Is a Biomarker for Recurrent Stage II Colorectal Cancer", ANN INTERN MED., vol. 131, no. 11, 7 December 1999 (1999-12-07), pages 805 - 812, XP002943298 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8535914B2 (en) * | 2005-01-21 | 2013-09-17 | Canon Kabushiki Kaisha | Probe, probe set and information acquisition method using the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020012931A1 (en) | High specificity marker detection | |
US10648036B2 (en) | Receptor gene for peptide cancer antigen-specific T cell | |
Iinuma et al. | Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele‐specific amplification of p53 and K‐ras genes in patients with colorectal cancer | |
Zhou et al. | Marker expression in circulating cancer cells of pancreatic cancer patients | |
US20050014208A1 (en) | Method and kit for diagnosing or controlling the treatment of breast cancer | |
EP3149210B1 (en) | Method for lung cancer diagnosis | |
US6576423B2 (en) | Specific mucin expression as a marker for pancreatic cancer | |
Dardaei et al. | The detection of disseminated tumor cells in bone marrow and peripheral blood of gastric cancer patients by multimarker (CEA, CK20, TFF1 and MUC2) quantitative real-time PCR | |
JP2018513679A (en) | Digital analysis of circulating tumor cells in blood samples | |
WO2019214063A1 (en) | Method for detecting circulating tumor cells | |
Ghossein et al. | Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction | |
EP1356294A2 (en) | Laminin alpha 4 subunit as a diagnostic indicator of malignant tumors | |
Fricke et al. | Synovial sarcoma microvesicles harbor the SYT-SSX fusion gene transcript: comparison of different methods of detection and implications in biomarker research | |
Shibata et al. | Detection of ras gene mutations in peripheral blood of carcinoma patients using CD45 immunomagnetic separation and nested mutant allele specific amplification. | |
Shimazui et al. | Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma | |
Oda et al. | Reverse transcriptase-polymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas | |
JPWO2015137406A1 (en) | A method for differential evaluation of squamous cell lung cancer and lung adenocarcinoma | |
Lopez-Munoz et al. | Markers of circulating breast cancer cells | |
KR102380529B1 (en) | Circulating tumor cell based biomarker composition for diagnosis and prognosis of metastatic prostate cancer | |
JP2004151003A (en) | Inspection method of muc1 and keratin19 | |
Teama et al. | Detection of circulating tumor cells by nested RT-PCR targeting EGFR/CEA/CK20mRNAs in colorectal carcinoma patients | |
JP7374196B2 (en) | Genetic markers for Helicobacter pylori-related diseases | |
Zehentner | Breast Cancer Patients Before, During or After Treatment: Circulating Tumor Cells in Peripheral Blood Detected by Multigene Real-Time Reverse Transcriptase-Polymerase Chain Reaction | |
US20060246430A1 (en) | Method and kit for the diagnosis or treatment control of intestinal carcinoma | |
JP2000069969A (en) | PRIMER DNA AND DETECTION OF mRNA WHICH CODES FOR PROSTATE-SPECIFIC ANTIGEN USING THE SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 570844 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2404428 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001922738 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001922738 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001922738 Country of ref document: EP |